C92.12 Chronic myeloid leukemia, BCR/ABL-positive, in relapse

Name of the Condition

• Chronic myeloid leukemia, BCR/ABL-positive, in relapse

Summary

Chronic myeloid leukemia (CML) is a cancer of the bone marrow and blood, characterized by the overproduction of abnormal white blood cells. The BCR/ABL-positive subtype is defined by the presence of the BCR/ABL fusion gene, a key genetic abnormality that drives the disease. In relapse, the disease reactivates after a period of remission, with detectable signs of active cancer despite prior treatment.

Causes

CML is primarily caused by a genetic mutation resulting in the BCR/ABL fusion gene. This gene produces an abnormal tyrosine kinase protein that disrupts normal cell regulation, leading to uncontrolled proliferation of myeloid cells. The mutation occurs spontaneously in most cases and is not inherited.

Risk Factors

• Age: Most common in adults, with incidence increasing after age 60.
• Gender: Slightly more prevalent in males.
• Exposure to high levels of ionizing radiation.
• No significant family history or inherited genetic predisposition.

Symptoms

• Fatigue or weakness
• Unexplained weight loss or fever
• Night sweats
• Enlarged spleen or abdominal discomfort
• Frequent infections
• Anemia or easy bruising/bleeding

Diagnosis

Diagnosis involves blood tests to detect abnormal white blood cell counts, followed by a bone marrow biopsy to confirm the presence of the BCR/ABL fusion gene. Cytogenetic or molecular testing may also be used to assess disease activity and detect relapse.

Treatment Options

• Tyrosine kinase inhibitors (TKIs) to target the BCR/ABL protein.
• Reintroduction or adjustment of prior therapies.
• Consideration of alternative treatments if resistance develops.
• Supportive care to manage symptoms and complications.

Prognosis and Follow-Up

Prognosis depends on the timing and nature of relapse, response to treatment, and overall health. Regular monitoring with blood tests and bone marrow assessments is essential to detect further changes. Long-term follow-up is recommended to manage ongoing risks.

Complications

• Disease progression to advanced phases (e.g., accelerated or blast crisis).
• Resistance to targeted therapies.
• Increased risk of infections due to impaired immune function.
• Anemia, thrombocytopenia, or other cytopenias.

Lifestyle & Prevention

• Avoid exposure to ionizing radiation when possible.
• Maintain regular medical check-ups for early detection.
• Follow treatment plans as prescribed to minimize relapse risk.
• Supportive care measures to manage symptoms and maintain quality of life.

When to Seek Professional Help

Seek immediate medical attention if experiencing severe symptoms such as uncontrolled bleeding, high fever, or sudden worsening of fatigue. Regular follow-up is critical for monitoring disease status and adjusting treatment as needed.

Tips for Medical Coders

Document the presence of relapse, including clinical evidence (e.g., rising BCR/ABL levels, symptom recurrence) and treatment response. Ensure the BCR/ABL-positive status is clearly recorded, as it is a key diagnostic criterion. Use this code only when relapse is confirmed and documented.